Approval · Notice of Compliance 16402 · 2014
SYLVANT: Notice of Compliance 16402
Issued December 3, 2014
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 16402
- Date
- December 3, 2014
- Company
- Janssen Inc.Toronto, Ontario, Canada
- Product type
- Biologic
- Submission
- New Drug Submission (NDS)
- Submission class
- Priority-NAS
- Therapeutic class
- Interleukin-6 antagonist
Products in this notice
Medicinal ingredients
- SILTUXIMAB 100 MG per VIAL
- SILTUXIMAB 400 MG per VIAL